And that could be a good thing ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

OpenAI has talked about how having an automated AI researcher was on its roadmap, and it’s shown the first glimpses of that ...

On July 4, 2026, Vitalik Buterin published the most consequential Ethereum protocol document in four years: an updated "Lean Ethereum" strawmap that commits the world's second-largest blockchain to ...

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

Spread the love“`html Artificial Intelligence (AI) has transcended its traditional role as a tool for human usage, evolving into a powerful force capable of creating and improving itself. This ...

Sakana AI has opened a Recursive Self-Improvement Lab to test whether AI systems can help redesign and optimize future AI systems, a bet aimed at reducing frontier AI’s dependence on brute-force ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...